Determination of free therapeutic certolizumab
Certolizumab is the Fab’ fragment of a recombinant humanised antibody conjugated to polyethylene glycol (PEG) and is therefore also known as “certolizumab pegol”. Certolizumab pegol (Cimzia®) is a TNF-alpha inhibitor used for the treatment of chronic inflammatory diseases, such as Crohn’s disease and rheumatoid arthritis. The IDKmonitor Certolizumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free certolizumab therapeutic drug in serum and EDTA plasma samples allowing clinicians to evaluate the drug efficacy and investigate primary non-response, loss of response and non-remission.